Position	Rank	AAs	Comment
128	1	T	A128T is a non-polymorphic mutation selected in vitro by EVG.  It does not appear to reduce INI susceptibility.
66	1	K	T66K is a non-polymorphic mutation selected in patients receiving EVG.  It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and potential low-level DTG resistance.
66	2	I	T66I is a non-polymorphic mutation selected in patients receiving EVG.  It reduces EVG susceptibility ~15-fold.
66	3	A	T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INI-resistance mutations.  It reduces EVG susceptibility ~10-fold.  It does not appear to reduce RAL or DTG susceptibility.
68	1	V	L68V is a polymorphic accessory mutation reported in patients receiving EVG.  It may synergistically reduce EVG susceptibility in combination with E92Q.
263	1	K	R263K is a non-polymorphic mutation selected in patients receiving RAL and DTG and in vitro by EVG and DTG.  It reduces RAL, DTG, and EVG susceptibility ~2-fold, 2-fold, and 4-fold, respectively.
74	1	MI	L74M/I are polymorphic accessory mutations selected by each of the INIs.
138	1	KA	E138K/A/T are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG.  They usually occur in combination with Q148 mutations.  Alone they do not reduce INI susceptibility.  However they are associated with >100-fold reduced RAL and EVG susceptibility and up to 10-fold reduced DTG susceptibility when they occur in combination with Q148 mutations.
138	2	T	E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG.  They usually occur in combination with Q148 mutations.  Alone they do not reduce INI susceptibility.  However they are associated with >100-fold reduced RAL and EVG susceptibility and up to 10-fold reduced DTG  E138T is a rare non-polymorphic INI-selected mutation that has been reported to have an effect similar to E138K/A.
138	3	D	E138D is a polymorphism that occurs in 1% to 2% of viruses from INI-naive patients.  It does not appear to be selected by INIs or to reduce INI susceptibility.
140	1	SAC	G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG.  Alone, they do not reduce INI susceptibility.  However, in combination with Q148 mutations they are associated with a >100-fold reduction in RAL and EVG susceptibility and up to 10-fold reduction in DTG susceptibility.
143	1	CR	Y143C/R are non-polymorphic mutations selected by RAL.  Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively.  In combination with T97A and other accessory mutations they reduce RAL susceptibility >100-fold.  Alone, Y143C/R have minimal effects on EVG susceptibility.  However, they are associated with ~10-fold reduced EVG susceptibility when they occur in combination with two or more accessory INI-resistance mutations.  Y143 mutations do not reduce DTG susceptibility.
143	2	H	Y143C/R are non-polymorphic mutations selected by RAL.  Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively.  In combination with T97A and other accessory mutations they reduce RAL susceptibility >100-fold.  Y143H is a less-common mutation at this position.  It is likely a transitional mutation between the wildtype Y and the 2-base pair mutant R.
143	3	KGSA	Y143K/G/S/A are extremely rare mutations that reduce RAL susceptibility ~5 to 10-fold.
145	1	S	P145S is a rare non-polymorphic mutation selected in vitro by EVG and rarely in patients receiving EVG.  It causes high-level resistance to EVG but not to RAL or DTG.
146	1	P	Q146P is a rare non-polymorphic mutation selected in vitro by EVG.  It reduces EVG susceptibility ~10-fold.
147	1	G	S147G is a non-polymorphic mutation selected in patients receiving EVG.  It reduces EVG susceptibility ~5 to 10-fold.  It does not reduce RAL or DTG susceptibility.
148	1	HKR	Q148H/K/R are non-polymorphic mutations selected by RAL and EVG.  Alone, Q148H reduces RAL and EVG susceptibility ~5 to 10-fold.  Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold.  In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility >100-fold.  Alone, Q148H/K/R have minimal effects on DTG susceptibility.  In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility ~10 to 20-fold.
148	2	N	Q148H/K/R are non-polymorphic mutations selected by RAL and EVG.  In combination with G140S/A or E138K/A, they reduce RAL and EVG susceptibility >100-fold.  In combination with G140S/A/C and/or E138K/A, they reduce DTG susceptibility ~10 to 20-fold.  Q148N has not been studied phenotypically but it is also a nonpolymorphic INI-selected mutation that usually occurs in combination With G140S/A.
151	1	I	V151I is a polymorphic mutation selected in patients receiving RAL and in vitro by EVG.  It appears to have little or no effect on INI susceptibility.
151	2	A	V151A is an extremely rare non-polymorphic mutation selected in vitro by an investigational INI.  It is associated with ~4-fold and 12-fold reduced susceptibility to RAL and EVG, respectively.
151	3	L	V151L is an extremely rare non-polymorphic mutation selected in vitro by early investigational INIs but not in patients receiving current INIs.  It reduces susceptibility to RAL, EVG, and DTG ~10-fold, 40-fold, and 3-fold, respectively.
153	1	YF	S153Y/F are extremely rare non-polymorphic mutations selected in vitro by EVG and DTG.  S153Y/F reduce RAL and DTG susceptibility ~2-fold and EVG susceptibility ~4-fold.
155	1	H	N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG.  Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively.  N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.
155	2	ST	N155H is a non-polymorphic mutation selected in patients receiving RAL and EVG.  Alone, it reduces RAL and EVG susceptibility ~15-fold and 30-fold, respectively.  N155H has been selected by DTG in RAL-experienced patients but alone does not reduce DTG susceptibility.  N155S/T are rare non-polymorphic mutations selected in vitro by investigational INIs.  N155S/T reduce RAL and EVG susceptibility somewhat less than does N155H.
92	1	Q	E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG.  It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold.  It is the most common INI-resistance mutation associated with virological failure on an EVG-containing regimen.  It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold.
92	2	V	E92V is a rare non-polymorphic mutation selected in vitro by an investigational INI.  It reduces RAL and EVG susceptibility by 10-fold and 40-fold, respectively.
92	3	G	E92G is a non-polymorphic mutation selected in patients receiving EVG.  It reduces EVG susceptibility ~10-fold.  It does not reduce RAL or DTG susceptibility.
157	1	Q	E157Q is a polymorphic accessory mutation weakly selected in patients receiving RAL.  E157Q reduces RAL and EVG susceptibility ~5-fold and 2-fold, respectively.
95	1	K	Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG.  Alone, it has little if any effect on INI susceptibility.
97	1	A	T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons.  It is selected by RAL and EVG.  Alone, it has minimal if any effect on INI susceptibility but in combination with Y143C/R it contributes to a marked reduction in RAL susceptibility.
163	1	RK	G163R/K are non-polymorphic mutations in all subtypes except subtype F.  They are commonly selected in patients receiving RAL.  Their effect on INI susceptibility has not been well studied.
230	1	R	S230R is a non-polymorphic accessory mutation selected by RAL and EVG.  It appears to have minimal, if any, effect on INI susceptibility.
230	2	N	S230N is a polymorphism that is not associated with reduced INI susceptibility.
114	1	Y	H114Y is an extremely rare non-polymorphic mutation selected in vitro by EVG.  It does not appear to be associated with significantly reduced INI susceptibility.
51	1	Y	H51Y is an uncommon non-polymorphic accessory mutation selected in patients receiving RAL and EVG.  It is also selected in vitro DTG.  Alone, H51Y reduces EVG susceptibility 2 to 3-fold.  It does not reduce RAL or DTG susceptibility.  However, the combination of H51Y and R263K is associated with ~5-fold reduced DTG susceptibility.
118	1	R	G118R is an extremely rare non-polymorphic mutation that has been selected by RAL.  In was reported to reduce RAL and EVG susceptibility ~10-fold and ~3-fold respectively.  G118R has been selected in vitro by DTG and reported to reduce DTG susceptibility ~3-fold.
121	1	Y	F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG.  It has been reported rarely in patients receiving RAL.  It reduces susceptibility to RAL ~5-fold and to EVG ~10-fold.  It does not appear to reduce DTG susceptibility.

